Spots Global Cancer Trial Database for Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Official Title:
Study ID: NCT00037804
Interventions
Study Description
Brief Summary: Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Center, Detroit, Michigan, United States
Research Center, New Brunswick, New Jersey, United States
Research Center, Nashville, Tennessee, United States
Research Center, Marshfield, Wisconsin, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
